This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Pharynx, unspecified
CD2_BENIGN_PHARYNX_NOS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleNone |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D10
- Name in latin
- Neoplasma benignum pharyngis non specificatum
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Pharynx, unspecified
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Pharynx, unspecified
- Benign neoplasm of mouth and pharynx
- Benign neoplasm of mouth and pharynx
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 272 | 162 | 110 |
| Unadjusted period prevalence (%) | 0.05 | 0.06 | 0.05 |
| Median age at first event (years) | 55.51 | 53.76 | 58.09 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 236
- Matched controls
- 2360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D10.9
ICD-10 Finland
Benign neoplasm: Pharynx, unspecified
16384.0
290.4
216
*
ENA10
NOMESCO Finland
Biopsy of pharynx
123.4
39.1
41
*
130
Kela drug reimbursment
Malignant tumour
+∞
24.4
23
*
21099
ICD-8 Finland
Benign neoplasm of buccal cavity and pharynx, Pharynx unspecified
+∞
15.8
15
*
JDB10
NOMESCO Finland
Percutaneous gastrostomy
45.6
14.3
17
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
7.8
14.2
33
48
WF002
NOMESCO Finland
Radical radiotherapy
79.9
13.7
15
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
13.7
13
*
EJA10
NOMESCO Finland
Biopsy of tongue or floor of mouth
16.3
13.4
21
14
UJC01
NOMESCO Finland
Scopy of lower throat
73.9
12.7
14
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
12.6
12
*
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
136.9
12.6
13
*
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
136.9
12.6
13
*
WX408
NOMESCO Finland
General anesthesy, balanced
3.2
12.2
77
313
504
Kela drug reimbursment
Conditions requiring daily forced enteral nutrition
68.4
11.7
13
*
EMA10
NOMESCO Finland
Biopsy of tonsil
+∞
11.5
11
*
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
37.0
11.4
14
*
EHA10
NOMESCO Finland
Biopsy of palate
45.6
11.0
13
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
5.3
10.8
33
70
H02AB02
ATC
dexamethasone; systemic
17.0
10.5
16
10
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
10.5
10
*
ENB00
NOMESCO Finland
Excision or exploration of lesion of pharynx
+∞
10.5
10
*
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
57.4
9.7
11
*
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
28.7
8.6
11
*
XX3DW
NOMESCO Finland
Time consuming IT work
5.0
8.3
26
57
GDA98
NOMESCO Finland
Other bronchoscopic incision, excision of lesion or repair of lung
46.5
7.8
9
*
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
+∞
7.3
7
*
115
Kela drug reimbursment
Breast cancer
+∞
7.3
7
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
7.3
7
*
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
+∞
7.3
7
*
D10.5
ICD-10 Finland
Benign neoplasm: Other parts of oropharynx
+∞
7.3
7
*
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
7.3
7
*
C50.41
ICD-10 Finland
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
+∞
7.3
7
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
7.3
7
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
2.4
7.2
73
374
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
8.3
7.2
15
19
A02BC02
ATC
pantoprazole; systemic
2.1
6.9
155
1121
EP1AE
NOMESCO Finland
Neck ultrasound examination
6.0
6.9
18
32
A04AA02
ATC
granisetron; systemic, transdermal
41.3
6.8
8
*
D10.19
ICD-10 Finland
Benign tumor of the tongue UNS
23.3
6.7
9
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
71.7
6.5
7
*
EN1AD
NOMESCO Finland
CT examination of mouth and soft tissues of neck
18.6
6.3
9
5
YA1VG
NOMESCO Finland
MRI examination of head and neck with high intesity magnet for dose design of radiotherapy
+∞
6.3
6
*
ZX080
NOMESCO Finland
Image guided radiotherapy
+∞
6.3
6
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
6.3
6
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
6.3
6
*
A07AA02
ATC
nystatin; oral
4.0
6.1
23
62
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
21
29
7.76
14.61
1.2
1.1
—
—
—
0
0
156
971
2.42
11.47
7.1
5.0
1.2
1.2
mmol/l
0.59
123
836
141
868
2.30
10.27
6.5
4.6
1.2
1.2
mmol/l
0.75
126
779
133
820
2.22
9.42
4.8
3.3
36.0
36.2
g/l
0.16
125
762
83
432
2.33
8.73
1.7
1.5
—
—
—
0
0
33
108
3.34
8.46
1.6
1.5
—
—
—
0
0
100
622
1.96
6.32
3.8
2.0
2.3
2.4
mmol/l
0.70
87
527
43
193
2.46
6.16
7.3
6.1
1.7
1.4
mmol/l
0.21
30
156
133
921
1.87
5.98
4.5
3.4
—
—
—
0
0
129
892
1.85
5.77
2.4
2.3
74.5
77.6
nmol/l
0.58
114
785
27
101
2.86
5.52
10.1
7.9
0.6
0.7
%
0.51
27
101
108
716
1.84
5.46
3.7
2.8
—
—
—
0
0
27
102
2.83
5.43
10.1
7.9
1.4
1.6
%
0.53
27
102
155
1165
1.77
5.00
10.8
6.0
4.3
4.2
e9/l
0.31
136
1013
53
284
2.08
4.96
1.7
1.6
—
—
—
0
0
59
339
1.95
4.53
2.9
2.4
0.9
0.9
e6/l
0.03
40
184
68
410
1.88
4.52
1.6
1.6
528.3
441.6
pmol/l
1.30
51
347
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
45
3.47
4.39
2.1
2.5
0.3
0.4
u/ml
—
8
26
85
554
1.78
4.38
3.8
2.6
0.4
0.4
e6/l
0.05
65
403
196
1621
1.75
4.10
8.4
5.1
76.4
75.3
u/l
0.23
190
1494
59
351
1.87
4.06
3.1
2.0
2.4
2.4
mmol/l
0.25
54
304
38
197
2.08
3.86
1.8
1.6
—
—
—
0
0
247
2222
2.21
3.65
19.3
11.0
25.7
21.5
mg/l
1.36
212
1688
15
51
3.05
3.63
2.7
3.9
—
—
—
0
0
31
152
2.17
3.63
4.4
3.2
82.0
78.5
ng/l
0.12
24
137
53
316
1.84
3.61
3.1
2.6
1.8
2.5
e6/l
0.43
35
162
265
2496
3.40
3.52
28.0
16.3
132.9
137.1
g/l
4.57
260
2462
80
542
1.67
3.49
2.5
2.2
329.9
7171.1
umol/l
2.44
66
476
37
199
1.99
3.41
1.8
1.6
—
—
—
0
0
231
2053
1.83
3.20
20.5
11.9
40.5
40.5
%
0.04
159
1538
7
11
6.50
3.20
2.6
2.7
2.8
3.4
nmol/l
—
7
11
231
2054
1.83
3.19
5.9
4.6
2.1
2.5
mu/l
0.31
208
1876
69
461
1.67
3.15
3.0
1.8
—
—
—
0
0
17
69
2.56
3.02
1.1
1.1
—
—
—
0
0
194
1665
1.58
2.88
4.3
3.9
14.6
11.0
mm/h
2.05
177
1522
197
1697
1.58
2.87
5.0
3.9
14.8
14.8
pmol/l
0.01
172
1541
9
23
4.01
2.80
1.4
1.3
—
—
—
0
0
33
184
1.90
2.76
4.1
2.8
—
—
—
0
0
11
37
3.06
2.72
1.4
1.5
—
—
—
0
0
11
37
3.06
2.72
1.4
1.1
—
—
—
0
0
95
707
1.53
2.71
2.7
2.6
28.0
31.9
u/l
1.06
90
669
81
583
1.55
2.69
3.1
3.1
2351.1
1285.3
ng/l
0.44
65
482
16
68
2.44
2.61
1.1
1.1
—
—
—
0
0
28
152
1.94
2.54
2.7
2.0
68.8
62.8
ml/min/173m2
—
9
62
130
1046
1.47
2.49
5.5
4.6
0.0
0.0
estimate
0.00
24
177
129
1039
1.46
2.44
4.2
3.3
0.0
0.0
estimate
0.00
23
177
5
8
6.34
2.38
2.2
1.4
19.0
19.6
ug/l
—
5
8
59
406
1.58
2.36
1.3
1.3
18.7
35.8
iu/ml
1.37
16
130
22
113
2.03
2.33
1.0
1.0
—
—
—
0
0
68
485
1.54
2.32
2.0
1.9
2.7
2.9
mg/l
0.26
58
402
70
503
1.53
2.31
1.3
1.3
1.6
1.5
u/ml
0.03
15
131
11
41
2.75
2.30
1.8
1.9
127.0
132.6
g/l
—
5
26
130
1065
1.42
2.17
4.1
3.4
0.0
0.0
estimate
0.50
23
169
73
537
1.49
2.15
4.1
3.7
0.0
0.0
estimate
0.00
22
173
230
2102
1.61
2.14
18.0
9.9
85.4
82.5
ml/min/173m2
1.12
181
1675
106
841
1.43
2.10
3.2
3.4
26.0
37.6
ng/l
0.71
74
566
7
20
3.56
2.07
1.4
1.4
—
—
—
0
0
32
195
1.73
2.04
2.9
1.9
63.2
30.4
u/l
0.55
24
166
67
489
1.49
2.04
1.4
1.5
22.7
21.6
nmol/l
0.18
55
413
18
91
2.05
2.00
2.8
2.2
1.4
1.3
%
0.14
18
91
22
120
1.91
1.99
1.7
1.3
—
—
—
0
0
52
362
1.54
1.97
2.0
1.6
1218.8
1207.5
nmol/l
0.03
36
274
25
143
1.82
1.97
5.0
2.5
4.3
4.5
kpa
0.18
25
137
10
40
2.56
1.85
1.6
1.1
—
—
—
0
0
10
40
2.56
1.85
1.6
1.1
—
—
—
0
0
114
932
1.38
1.85
3.0
2.6
114.3
106.5
ug/l
0.15
99
854
7
23
3.10
1.81
1.7
1.3
—
—
—
0
0
6
18
3.38
1.75
1.5
1.4
—
—
—
0
0
6
19
3.20
1.67
1.8
1.2
—
—
—
0
0
18
99
1.88
1.61
1.5
1.6
—
—
—
0
0
7
26
2.74
1.59
1.7
1.3
—
—
—
0
0
20
115
1.80
1.57
1.6
1.4
—
—
—
0
0
35
236
1.55
1.54
2.5
2.1
19.2
24.6
%
1.44
29
209
18
101
1.84
1.53
8.3
6.2
25.8
25.3
mmol/l
0.25
18
101
21
128
1.69
1.38
1.7
2.2
—
—
—
0
0
17
99
1.76
1.30
1.3
2.2
—
—
—
0
0
37
265
1.46
1.25
26.8
17.0
1.0
1.2
inr
—
6
49
8
37
2.20
1.22
1.8
1.3
—
—
—
0
0
0
33
0.00
1.17
0.0
1.2
—
1.5
—
0
13
0
34
0.00
1.16
0.0
1.1
—
—
—
0
0
61
483
1.34
1.16
4.1
3.4
25.7
24.8
%
0.15
26
201
22
143
1.59
1.15
3.3
2.4
12.8
15.4
nmol/l
0.83
17
129
5
20
2.53
1.15
2.4
4.8
—
—
—
0
0
12
65
1.89
1.15
3.8
2.2
3841.1
3792.3
u/l
—
7
25
250
2399
1.52
1.08
12.9
8.4
24.8
26.6
u/l
1.21
243
2316
7
33
2.15
1.06
2.1
1.8
—
—
—
0
0
9
47
1.95
1.03
1.4
1.6
—
—
—
0
0
35
259
1.40
1.01
11.3
6.3
—
—
—
0
0
5
23
2.20
0.98
1.2
1.5
—
—
—
0
0
7
36
1.97
0.97
1.9
1.3
—
—
—
0
0
11
62
1.81
0.95
1.6
1.6
0.5
2.4
ug/l
1.29
11
56
9
51
1.79
0.95
1.1
1.3
—
51.5
—
0
5
12
71
1.72
0.90
1.2
1.6
—
—
—
0
0
13
79
1.68
0.89
1.8
2.4
—
—
—
0
0
6
30
2.02
0.87
1.8
1.2
—
—
—
0
0
6
31
1.96
0.85
1.3
1.2
—
—
—
0
0
11
65
1.72
0.83
1.4
1.3
—
—
—
0
0
6
32
1.89
0.82
1.3
1.2
—
—
—
0
0
12
75
1.63
0.76
1.3
1.6
—
—
—
0
0
48
392
1.27
0.75
1.4
1.3
16.8
8.4
u/ml
0.32
16
155
43
347
1.28
0.74
2.7
2.5
0.7
0.7
ug/l
0.32
19
215
5
26
1.94
0.71
1.0
1.0
—
—
—
0
0
5
26
1.94
0.71
1.2
1.1
—
—
—
0
0
99
883
1.19
0.67
2.2
1.9
99.2
97.6
pmol/l
0.11
48
435
56
473
1.23
0.66
1.7
1.7
2.2
0.9
mg/l
1.51
41
353
92
822
1.18
0.61
4.3
3.4
—
—
—
0
0
10
64
1.58
0.59
1.7
1.8
—
—
—
0
0
6
36
1.68
0.57
1.2
1.4
—
—
—
0
0
196
1867
1.18
0.56
24.6
13.1
14.0
13.6
%
1.70
191
1837
11
74
1.51
0.54
1.7
1.2
—
—
—
0
0
228
2203
1.22
0.54
5.0
4.4
6.1
5.9
mmol/l
1.29
208
2023
11
75
1.49
0.51
2.5
2.1
848.6
297.3
ug/l
0.29
11
70
152
1433
1.14
0.46
3.3
3.2
—
—
—
0
0
216
2086
1.17
0.46
7.2
5.6
41.4
39.5
mmol/mol
1.82
197
1954
8
58
1.39
0.42
1.1
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
46
402
1.17
0.40
3.7
3.8
40.5
163.7
ng/l
1.72
37
301
0
18
0.00
0.40
0.0
1.3
—
2.0
—
0
7
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
9
66
1.38
0.39
1.6
1.3
—
—
—
0
0
67
606
1.14
0.38
2.0
1.7
1.7
1.4
mmol/l
1.38
58
520
5
37
1.36
0.37
1.4
1.1
—
—
—
0
0
17
212
0.79
0.37
1.6
1.6
—
—
—
0
0
9
70
1.30
0.37
1.3
1.7
—
—
—
0
0
6
41
1.47
0.36
2.0
1.3
—
—
—
0
0
11
82
1.36
0.34
1.4
1.8
—
163.3
—
0
6
6
45
1.34
0.34
1.3
1.5
—
—
—
0
0
157
1507
1.10
0.30
3.3
2.9
39.9
43.4
u/l
0.32
148
1414
66
617
1.09
0.22
4.3
3.5
2.0
1.8
ug/l
0.25
58
555
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
12
0.00
0.21
0.0
2.8
—
563.6
—
0
12
0
13
0.00
0.21
0.0
2.1
—
—
—
0
0
6
48
1.26
0.20
1.0
1.3
—
—
—
0
0
13
154
0.84
0.19
1.1
1.3
164.0
152.3
iu/ml
—
5
60
6
51
1.18
0.19
1.3
1.4
—
1.1
—
0
6
6
51
1.18
0.19
1.0
1.1
—
—
—
0
0
6
53
1.13
0.19
1.0
1.2
—
—
—
0
0
213
2159
0.94
0.13
4.3
3.9
1.3
1.3
mmol/l
0.50
195
1991
11
126
0.87
0.11
1.7
1.5
—
—
—
0
0
7
65
1.08
0.08
1.4
1.3
645.7
409.6
mg/l
—
7
60
7
66
1.06
0.08
3.4
1.8
26.7
36.8
nmol/l
—
7
61
7
80
0.87
0.07
2.1
1.5
—
—
—
0
0
9
85
1.06
0.07
1.4
1.7
—
—
—
0
0
37
358
1.04
0.04
1.6
1.5
—
—
—
0
0
229
2302
0.97
0.04
5.6
4.9
2.7
2.8
mmol/l
0.25
208
2144
27
280
0.96
0.03
4.7
4.7
27.6
32.3
%
1.85
15
184
28
290
0.96
0.03
3.6
2.2
—
—
—
0
0
25
257
0.97
0.01
3.3
2.0
—
—
—
0
0
27
277
0.97
0.01
1.5
1.8
1.6
1.5
%
0.30
21
244
11
104
1.06
0.01
1.9
2.4
0.1
0.2
e6/l
0.52
11
99
17
167
1.02
0.00
1.8
1.3
—
52.7
—
0
11
226
2264
0.99
0.00
4.9
4.4
4.7
4.7
mmol/l
0.10
209
2112
224
2244
0.99
0.00
4.8
4.3
1.4
1.5
mmol/l
0.65
204
2090
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
7
69
1.01
0.00
1.6
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
6.5
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
7
73
0.96
0.00
2.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
0.00
0.0
1.0
—
1527.1
—
0
9
0
8
0.00
0.00
0.0
1.6
—
—
—
0
0
7
73
0.96
0.00
2.0
1.5
—
—
—
0
0
7
73
0.96
0.00
2.0
1.5
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_PHARYNX_NOS_EXALLC – Benign neoplasm: Pharynx, unspecified
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).